The capital market is one of the most critical pillars of financial markets, which plays an important role in countries' economies. With the increasing development of international trade and the free flow of capital, financial asset prices spread to other assets. The extend is increasing with the expansion of communication networks as well as the close connection of financial markets to each other. Therefore, the state of a market is not only specific to itself but also affects other financial markets. Global oil, gold, and basic metal prices, including palladium, significantly influence the American financial markets. Due to the importance of the Nasdaq index for investors' investment decisions, this study analyzes the impact of oil, gold, and palladium metal prices on the Nasdaq index monthly between 2016 and 2021. Based on the final model, the oil and gold markets significantly impact the Nasdaq index, while palladium has a less significant impact.

The worldwide prevalence of type 2 diabetes (T2D) and obesity has been a driving force behind the heavy research on glucagon-like peptide-1 receptor agonists (GLP-1RAs). Orforglipron, an innovative, oral, non-peptide GLP-1RA, is a major development in the therapeutic field, and it has the potential to make the delivery of drugs easier and more patient-friendly than the usual injections. The purpose of this scientometric study is to present the scientific works on orforglipron and thus portray its research landscape, important topics, and growing evidence base. A detailed examination of 101 scientific works (from 2023 to 2025) taken from the Scopus database has been done in this study. The documents were divided into categories depending on the type (e.g., clinical trial, review, meta-analysis), the theme dealt with, and the writer's background. The synthesis included research trends in focus, drug efficacy and safety outcomes, and positioning of the drug within the larger area of pharmacotherapy. The literature on orforglipron has just begun, with the first publications coming out in 2023. The data set consists of a substantial primary research foundation comprising clinical trials of all three Phases, plus a great number of reviews, meta-analyses, and editorial commentaries. The major research themes are: (1) Efficacy in Type 2 Diabetes and obesity, showing pronounced drops in HbA1c and body weight; (2) Safety and tolerability, where the main concern is with gastrointestinal adverse events; (3) Comparative effectiveness against other GLP-1RAs and multi-agonists; (4) Pharmacological characterization as a small-molecule agonist; and (5) The potential role of the drug in cardiovascular risk reduction and other areas that are yet to be explored. The scientific literature surrounding orforglipron is growing at a rapid pace and this indicates that there is a high interest in the drug's potential to change the management of T2D and obesity. The current evidence places it as a powerful, oral option to be administered instead of GLP-1RAs that are delivered by injection. The future research initiatives will probably be directed towards the investigation of the long-term cardiovascular outcomes, real-world effectiveness, and the use in a broader range of patients with different diseases.